Serum protein acrolein adducts: utility in detecting oxidant stress in hemodialysis patients and reversal using a vitamin E-bonded hemodialyzer.
Accumulating evidence indicates that protein modification by acrolein is one of the major hallmarks of atherosclerosis. The purpose of the present study was to evaluate the serum acrolein-modified protein adduct (Acr) level in end-stage renal disease (ESRD), and to elucidate the efficacy of vitamin E-bonded hemodialyzer in reducing Acr in a crossover trial. A significant increase in Acr was found in ESRD patients compared with healthy controls (p <.001). In ESRD, the Acr level of those patients with type 2 diabetes mellitus (DM) was significantly higher compared with the non-DM group (p <.05). Forty-one ESRD patients who exhibited Acr levels higher than the mean value in ESRD were treated by vitamin E-bonded hemodialyzer for 6 months. After 6 months of treatment, Acr levels were decreased to those found in healthy individuals (p <.001). When hemodialyzers were switched back from vitamin E bonded to the original regular ones, Acr levels increased to nearly their initial levels after 3 months (p <.001), compared with the 6 month time point. These results suggest the potential of Acr as an oxidative stress marker in ESRD, and that vitamin E-bonded hemodialyzer treatment is a reasonable approach to reduce oxidative stress in ESRD.
Noiri
Eisei
E
Department of Nephrology and Endocrinology, University of Tokyo, Tokyo, Japan. nori-tky@umi.ac.jp
Yamada
Satoshi
S
Nakao
Akihide
A
Tsuchiya
Masao
M
Masaki
Ichiro
I
Fujino
Katsuaki
K
Nosaka
Kazuo
K
Ozawa
Takashi
T
Fujita
Toshiro
T
Uchida
Koji
K
D000171:Acrolein / Q000097:blood* / Q000378:metabolism*; D000328:Adult; D000368:Aged; D000375:Aging / Q000097:blood; D001161:Arteriosclerosis / Q000097:blood / Q000150:complications / Q000378:metabolism; D015415:Biomarkers / Q000097:blood; D018592:Cross-Over Studies; D005260:Female; D006801:Humans; D007674:Kidney Diseases / Q000097:blood* / Q000150:complications / Q000378:metabolism / Q000517:prevention & control / Q000628:therapy; D008297:Male; D008875:Middle Aged; D018384:Oxidative Stress / Q000187:drug effects*; D006435:Renal Dialysis; D013997:Time Factors; D014810:Vitamin E / Q000008:administration & dosage* / Q000494:pharmacology*
D015415:Biomarkers; D014810:Vitamin E; D000171:Acrolein